Role of Nuclear Factor-kappa B Signaling in Anticancer Properties of Indole Compounds

Journal of Experimental and Clinical Medicine

Volumn 3, Issue 2, 2011, Pages 55-62

  Ahmad, Aamir ^a   Sakr, Wael A ^a   Rahman, K M Wahidur ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Diindolylmethane; Indole 3 carbinol; NF kB

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; DOCETAXEL; ERLOTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SURVIVIN; TAMOXIFEN;

BINDING AFFINITY; BREAST CANCER; CANCER RESISTANCE; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79954690864     PISSN: 18783317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jecm.2011.01.001     Document Type: Review

References (98)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
3. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
4. Lin Y., Bai L., Chen W., Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010, 14:45-55.
5. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010, 1805:167-180.
6. Ahmad A., Banerjee S., Wang Z., Kong D., Majumdar A.P., Sarkar F.H. Aging and inflammation: etiological culprits of cancer. Curr Aging Sci 2009, 2:174-186.
7. Luqman S., Pezzuto J.M. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 2010, 24:949-963.
8. Sarkar F.H., Li Y., Wang Z., Kong D. Cellular signaling perturbation by natural products. Cell Signal 2009, 21:1541-1547.
9. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010, 2:a000109.
10. Sarkar F.H., Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008, 13:2950-2959.
11. Rios J.L., Recio M.C., Escandell J.M., Andujar I. Inhibition of transcription factors by plant-derived compounds and their implications in inflammation and cancer. Curr Pharm Des 2009, 15:1212-1237.
12. Boone C.W., Kelloff G.J., Malone W.E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990, 50:2-9.
13. Lee M.M., Gomez S.L., Chang J.S., Wey M., Wang R.T., Hsing A.W. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003, 12:665-668.
14. Sarkar F.H., Li Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 2009, 35:597-607.
15. Ahmad A., Sakr W.A., Rahman K.M. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets 2010, 11:652-666.
16. Kim Y.S., Milner J.A. Targets for indole-3-carbinol in cancer prevention. J Nutr Biochem 2005, 16:65-73.
17. Aggarwal B.B., Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005, 4:1201-1215.
18. Rogan E.G. The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo 2006, 20:221-228.
19. Safe S., Papineni S., Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett 2008, 269:326-338.
20. Bradlow H.L. Review. Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer. In Vivo 2008, 22:441-445.
21. Acharya A., Das I., Singh S., Saha T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat Food Nutr Agric 2010, 2:166-177.
22. Rahman K.M., Sarkar F.H. Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells. J Steroid Biochem Mol Biol 2002, 80:191-201.
23. Rahman K.M., Aranha O., Sarkar F.H. Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 2003, 45:101-112.
24. Rahman K.M., Aranha O., Glazyrin A., Chinni S.R., Sarkar F.H. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 2000, 19:5764-5771.
25. Ahmad A, Ali S, Wang Z, Ali SA, Sethi S, Sakr WA, Rahman KM. 3, 3'-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through down-regulation of FoxM1. Int J Cancer 2010. In press, doi:10.1002/ijc.25839.
26. Sarkar F.H., Li Y. Indole-3-carbinol and prostate cancer. J Nutr 2004, 134:3493S-3498S.
27. Weng J.R., Tsai C.H., Kulp S.K., Chen C.S. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 2008, 262:153-163.
28. Steinmetz K.A., Potter J.D. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996, 96:1027-1039.
29. Michaud D.S., Spiegelman D., Clinton S.K., Rimm E.B., Willett W.C., Giovannucci E.L. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst 1999, 91:605-613.
30. Oganesian A., Hendricks J.D., Williams D.E. Long term dietary indole-3-carbinol inhibits diethylnitrosamine-initiated hepatocarcinogenesis in the infant mouse model. Cancer Lett 1997, 118:87-94.
31. Jin L., Qi M., Chen D.Z., Anderson A., Yang G.Y., Arbeit J.M. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res 1999, 59:3991-3997.
32. He Y.H., Friesen M.D., Ruch R.J., Schut H.A. Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenesis: inhibition of PhIP-DNA adduct formation, acceleration of PhIP metabolism, and induction of cytochrome P450 in female F344 rats. Food Chem Toxicol 2000, 38:15-23.
33. Kojima T., Tanaka T., Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 1994, 54:1446-1449.
34. Wong G.Y., Bradlow L., Sepkovic D., Mehl S., Mailman J., Osborne M.P. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 1997, 28-29:111-116.
35. Yuan F., Chen D.Z., Liu K., Sepkovic D.W., Bradlow H.L., Auborn K. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 1999, 19:1673-1680.
36. Holst B., Williamson G. A critical review of the bioavailability of glucosinolates and related compounds. Nat Prod Rep 2004, 21:425-447.
37. McDanell R., McLean A.E., Hanley A.B., Heaney R.K., Fenwick G.R. The effect of feeding brassica vegetables and intact glucosinolates on mixed-function-oxidase activity in the livers and intestines of rats. Food Chem Toxicol 1989, 27:289-293.
38. Shertzer H.G., Senft A.P. The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metabol Drug Interact 2000, 17:159-188.
39. Grose K.R., Bjeldanes L.F. Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 1992, 5:188-193.
40. Anderton M.J., Manson M.M., Verschoyle R.D., Gescher A., Lamb J.H., Farmer P.B. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 2004, 10:5233-5241.
41. Stresser D.M., Blanchard A.P., Turner S.D., Erve J.C., Dandeneau A.A., Miller V.P. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000, 28:1440-1448.
42. Karin M. The IkappaB kinase-a bridge between inflammation and cancer. Cell Res 2008, 18:334-342.
43. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759.
44. Haefner B. NF-kappa B: arresting a major culprit in cancer. Drug Discov Today 2002, 7:653-663.
45. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006, 66:2778-2784.
46. Wang Z., Sengupta R., Banerjee S., Li Y., Zhang Y., Rahman K.M. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 2006, 66:7653-7660.
47. Wu K., Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 2009, 29:241-254.
48. Shen H.M., Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
49. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40.
50. Sarkar F.H., Li Y., Wang Z., Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008, 27:293-319.
51. Cortes S.M., Rodriguez F.V., Sanchez P.I., Perona R. The role of the NFkappaB signalling pathway in cancer. Clin Transl Oncol 2008, 10:143-147.
52. Rahman K.M., Li Y., Sarkar F.H. Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer 2004, 48:84-94.
53. Rahman K.W., Sarkar F.H. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005, 65:364-371.
54. Rahman K.M., Sarkar F.H., Banerjee S., Wang Z., Liao D.J., Hong X., Sarkar N.H. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 2006, 5:2747-2756.
55. Bhuiyan M.M., Li Y., Banerjee S., Ahmed F., Wang Z., Ali S. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006, 66:10064-10072.
56. Kong D., Li Y., Wang Z., Banerjee S., Sarkar F.H. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007, 67:3310-3319.
57. Rahman K.M., Ali S., Aboukameel A., Sarkar S.H., Wang Z., Philip P.A., Sakr Wael Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007, 6:2757-2765.
58. Ahmad A., Kong D., Wang Z., Sarkar S.H., Banerjee S., Sarkar F.H. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009, 108:916-925.
59. Banerjee S., Wang Z., Kong D., Sarkar F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009, 69:5592-5600.
60. Ahmad A., Kong D., Sarkar S.H., Wang Z., Banerjee S., Sarkar F.H. Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 2009, 107:516-527.
61. Ali S., Banerjee S., Ahmad A., El-Rayes B.F., Philip P.A., Sarkar F.H. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 2008, 7:1708-1719.
62. Rahman K.M., Banerjee S., Ali S., Ahmad A., Wang Z., Kong D., Sakr W.A. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 2009, 69:4468-4475.
63. Kim E.J., Park H., Kim J., Park J.H. 3,3'-diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators. Mol Carcinog 2010, 49:672-683.
64. Aronchik I., Bjeldanes L.F., Firestone G.L. Direct inhibition of elastase activity by indole-3-carbinol triggers a CD40-TRAF regulatory cascade that disrupts NF-kappaB transcriptional activity in human breast cancer cells. Cancer Res 2010, 70:4961-4971.
65. Kassie F., Melkamu T., Endalew A., Upadhyaya P., Luo X., Hecht S.S. Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. Carcinogenesis 2010, 31:1634-1641.
66. Michnovicz J.J., Bradlow H.L. Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 1990, 82:947-949.
67. Michnovicz J.J., Bradlow H.L. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 1991, 16:59-66.
68. Michnovicz J.J., Hershcopf R.J., Naganuma H., Bradlow H.L., Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986, 315:1305-1309.
69. Bradlow H.L., Michnovicz J., Telang N.T., Osborne M.P. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991, 12:1571-1574.
70. Tiwari R.K., Guo L., Bradlow H.L., Telang N.T., Osborne M.P. Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 1994, 86:126-131.
71. Cover C.M., Hsieh S.J., Tran S.H., Hallden G., Kim G.S., Bjeldanes L.F. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 1998, 273:3838-3847.
72. Cover C.M., Hsieh S.J., Cram E.J., Hong C., Riby J.E., Bjeldanes L.F. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999, 59:1244-1251.
73. Howells L.M., Gallacher-Horley B., Houghton C.E., Manson M.M., Hudson E.A. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther 2002, 1:1161-1172.
74. Helbig G., Christopherson K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631-21638.
75. Kunigal S., Lakka S.S., Joseph P., Estes N., Rao J.S. Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res 2008, 14:3617-3626.
76. Hirbe A.C., Morgan E.A., Weilbaecher K.N. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr Pharm Des 2010, 16:1284-1290.
77. Weng J.R., Tsai C.H., Kulp S.K., Wang D., Lin C.H., Yang H.C., Ma Y., et al. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res 2007, 67:7815-7824.
78. Weng J.R., Tsai C.H., Omar H.A., Sargeant A.M., Wang D., Kulp S.K. OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling. Carcinogenesis 2009, 30:1702-1709.
79. Moiseeva E.P., Heukers R. Indole-3-carbinol-induced modulation of NF-kappaB signalling is breast cancer cell-specific and does not correlate with cell death. Breast Cancer Res Treat 2008, 109:451-462.
80. Chinni S.R., Li Y., Upadhyay S., Koppolu P.K., Sarkar F.H. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001, 20:2927-2936.
81. Li Y., Chinni S.R., Sarkar F.H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 2005, 10:236-243.
82. Le H.T., Schaldach C.M., Firestone G.L., Bjeldanes L.F. Plant-derived 3,3'-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 2003, 278:21136-21145.
83. Garikapaty V.P., Ashok B.T., Tadi K., Mittelman A., Tiwari R.K. Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 2006, 66:453-462.
84. Garikapaty V.P., Ashok B.T., Tadi K., Mittelman A., Tiwari R.K. 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 2006, 340:718-725.
85. Garcia M.G., Alaniz L.D., Russo R.I.C., Alvarez E., Hajos S.E. PI3 K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 2009, 33:288-296.
86. Heath E.I., Heilbrun L.K., Li J., Vaishampayan U., Harper F., Pemberton P. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res 2010, 2:402-411.
87. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001, 20:859-868.
88. Ali S., Banerjee S., Schaffert J.M., El-Rayes B.F., Philip P.A., Sarkar F.H. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem 2010, 110:171-181.
89. Lei P., Abdelrahim M., Cho S.D., Liu X., Safe S. Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3'-indoly)-1-(p-substituted phenyl)methanes. Mol Cancer Ther 2008, 7:3363-3372.
90. Guo J., Chintharlapalli S., Lee S.O., Cho S.D., Lei P., Papineni S. Peroxisome proliferator-activated receptor gamma-dependent activity of indole ring-substituted 1,1-bis(3'-indolyl)-1-(p-biphenyl)methanes in cancer cells. Cancer Chemother Pharmacol 2010, 66:141-150.
91. Sreevalsan S., Jutooru I., Chadalapaka G., Walker M., Safe S. 1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int J Oncol 2009, 35:1191-1199.
92. Li Y., Vandenboom T.G., Wang Z., Kong D., Ali S., Philip P.A. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010, 70:1486-1495.
93. Takada Y., Andreeff M., Aggarwal B.B. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005, 106:641-649.
94. Chen Y., Xu J., Jhala N., Pawar P., Zhu Z.B., Ma L. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006, 169:1833-1842.
95. Weng J.R., Omar H.A., Kulp S.K., Chen C.S. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini Rev Med Chem 2010, 10:398-404.
96. Wang Z., Yu B.W., Rahman K.M., Ahmad F., Sarkar F.H. Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip. Mol Cancer Ther 2008, 7:341-349.
97. Rahman K.W., Li Y., Wang Z., Sarkar S.H., Sarkar F.H. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006, 66:4952-4960.
98. Ali S., Varghese L., Pereira L., Tulunay-Ugur O.E., Kucuk O., Carey T.E., Wolf G.T., et al. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett 2009, 278:201-209.